Rejected at 10:35 a.m. May, 18, 2026 ] by mitchelnelson
Author: jfrehring123
Related Note: 1462122709023
Rationale for change

GLPs and DPPs also increase insulin and c-peptide per sketchy

Rejection reason

Please resubmit with an acceptable source. Please review suggestion guidelines, specifically rule #1: 📚 AnKing Step Deck Submission Guidelines

Text Text
Extra
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy
Sketchy 2
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize
Physeo
Empty field
Bootcamp
OME
Additional Resources
Empty field
One by one
Empty field
#AK_Step1_v12::#FirstAid::08_Endocrine::03_Physiology::10_Insulin::01_Synthesis::*Synthesis_Secretion #AK_Step1_v12::#SketchyPharm::05_GI_&_Endocrine::02_Diabetes::01_Insulin,_Sulfonylureas,_Meglitinides,_GLP-1_Agonists,_DPP-4_Inhibitors #AK_Step3_v12::#UWorld::5986 #AK_Step2_v12::#NBME::Free120 #AK_Step1_v12::#UWorld::Step::11565 #AK_Step1_v12::#Costanzo::Endocrine::09_Endocrine_Pancreas #AK_Step1_v12::#Pixorize::03_Pharmacology::07_Diabetes_Drugs_(New)::08_Meglitinide #PANCE::ENDO::diabetes #AK_Step2_v12::#FirstAid::03_Endocrinology::01_Disorders_of_Glucose_Metabolism::04_Hypoglycemia #AK_Step1_v12::#Pixorize::03_Pharmacology::08_Diabetes_Drugs_(Old)::05_Second-Gen_Sulfonylureas #AK_Step1_v12::#UWorld::Step::1655 #AK_Step1_v12::#Physeo::11_Pathology::02_Endocrine_Pathology::06_Endocrine_Pancreas #AK_Step1_v12::#AMBOSS::2x0TDR #AK_Step2_v12::#CMS::Surgery::Form_03 #AK_Step2_v12::#AMBOSS::8P0OgT #AK_Step2_v12::#NBME::Form13::Section_4 #AK_Step1_v12::#SketchyPath::06_Hepatobiliary::03_Pancreatic_Disease::02_Pancreatic_Cancer_&_Islet_Cell_Tumors #AK_Step1_v12::#FirstAid::08_Endocrine::04_Pathology::26_Pancreatic_islet_cell_tumors #AK_Step1_v12::#Pixorize::03_Pharmacology::08_Diabetes_Drugs_(Old)::04_First-Gen_Sulfonylureas #AK_Step1_v12::#UWorld::COMLEX::24766 #AK_Step2_v12::#AMBOSS::lh0vVf #AK_Other::#AK_Original_Decks::Step_1::Zanki_Step_Decks::Zanki_Endocrine::Endocrine_Physiology #AK_Step2_v12::#NBME::Form14::Section_1 #AK_Step1_v12::#Low/HighYield::1-HighYield #AK_Step1_v12::^Systems::Endocrine::Physiology #AK_Step2_v12::#UWorld::Step::2188 #AK_Step1_v12::#FirstAid::08_Endocrine::04_Pathology::26_Pancreatic_islet_cell_tumors::01_Insulinoma #AK_Step1_v12::#AMBOSS::3XaSBQ #AK_Step1_v12::#Bootcamp::Endocrinology::07_Pancreas::02_Insulin_Physiology #AK_Step1_v12::#B&B::09_Endocrinology::03_Pancreas::01_Insulin::Extra #AK_Step1_v12::#OME::04_Organ_Systems::06_Endocrine::05_Pancreas::01_The_Endocrine_Pancreas #AK_Step2_v12::#UWorld::COMLEX::104627 #AK_Step2_v12::#UWorld::Step::20217 #AK_Step2_v12::#UWorld::COMLEX::28006 #AK_Step1_v12::#B&B::09_Endocrinology::03_Pancreas::02_Glucagon_&_Hypoglycemia #AK_Step2_v12::#Bootcamp::Medicine::05_Endocrinology::01_Disorders_of_Glucose_Metabolism::09_Hypoglycemic_And_Islet_Cell_Disorders #AK_Step2_v12::!Shelf::Psych #AK_Step1_v12::#OME::PreClinical::04_Organ_Systems::06_Endocrine::05_Pancreas::01_The_Endocrine_Pancreas #AK_Step2_v12::#SketchyIM::05_Endocrinology::01_Diabetes_Mellitus::02_Diabetes_Management #AK_Step1_v12::#FirstAid::08_Endocrine::03_Physiology::10_Insulin #AK_Other::Only_Step_1&2_Overlap #AK_Step1_v12::#Pixorize::03_Pharmacology::07_Diabetes_Drugs_(New)::07_Sulfonylureas #AK_Step1_v12::#Bootcamp::Gastroenterology::07_Pancreas::08_Pancreatic_Neuroendocrine_Tumors #PANCE::EOR::IM